|
|
|
市場調查報告書
全球幹細胞研究市場（2017年止）：強勢產品線、慢性病相關之高未滿足需求、有利政府政策促進幹細胞研發
Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D
| 出版商 |
GBI Research |
| 出版日期 |
2011年11月 |
商品編碼 |
224311 |
| 內容資訊 |
英文 Pages: 160 |
| 價格 |
|
|
全球幹細胞研究市場（2017年止）：強勢產品線、慢性病相關之高未滿足需求、有利政府政策促進幹細胞研發 是由出版商GBI Research在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 160 價格從美金3500起跳。
本報告為，分析全球幹細胞研究及開發市場，並匯整整體市場結構、趨勢、目前幹細胞研究情形、臨床實驗詳細資訊、各國政府及企業之研究資金供應情形、各國市場趨勢、主要企業、大學簡介等，以下列摘要形式闡述。
第1章 目錄
第2章 簡介
第3章 市場概況
- 簡介
- 幹細胞研究種類
- 現況中幹細胞活用方式之種類
- 未滿足之需求
第4章 市場特徵
- 簡介
- 市場規模
- 治療費用
- 技術用框架
- 商業模式之種類
- 市場驅力
- 隨安全有效之藥劑觀點出發之未滿足需求，促使特定疾病之幹細胞研究有極大市場機會
- 促進美國ES細胞（胚胎幹細胞）研究之政治環境
- 隨IPS細胞（多功能人造幹細胞）之進步及對ES細胞依賴之好轉，使幹細胞治療之接受度增加
- 市場阻力及各種挑戰
- 因高額研究費用，增加幹細胞研發之巨額投資
- 高額治療費用及不明白之成本效益比導致目前不確實之醫療償還現況
- 倫理、法規、社會問題：即使影響變小但仍待解決
- 幹細胞研究之人才管理：維持高水準研究所需之重要領域
- 市場趨勢
- 幹細胞治療團：吸引投資之潛在機會
- 幹細胞治療團之ASLAP分析
- 聯邦政府之資金提供改善了幹細胞研究之環境
- 醫療藥物企業之參與促進幹細胞研發
- 幹細胞研究之PESTLE分析
- 幹細胞研究之SWOT分析
- 市場分析
第5章 產品線分析
- 藥物發現
- 已註冊臨床實驗藥物(IND)
- 臨床實驗前
- 第I階段臨床實驗
- 第II階段臨床實驗
- 第III階段臨床實驗
第6章 投資趨勢
- 幹細胞研究之投資展望
- 研究現況
- 法規體制
- 臨床開發
- 商業化模式
- 專利政策
- NIH（美國國立衛生研究院）未來對幹細胞研究投資之增加及影響
- BBSRC（英國生物技術與生物科學研究理事會）對幹細胞研究之資金供應
第7章 各國趨勢
- 各國幹細胞箱關企業
- 美國
- 英國
- 中國
- 荷蘭
- 新加坡
- 韓國
- 日本
- 印度
- 瑞典
- 丹麥
- 法國
- 德國
- 以色列
- 澳大利亞
- 加拿大
- 捷克共和國
第8章 企業合併、收購(M&A)
第9章 企業簡介
- Aastrom Biosciences
- Athersys Inc.
- Osiris Therapeutics
- Bioheart
- Aldagen
- Mesoblast
- Geron
- Advanced Cell Technology
- Cytori Therapeutics
- Pluristem Therapeutics
- Medistem
- NeoStem
- Helix Therapeutics
- StemCells Inc.
第10章 大學簡介
- University of California, San Francisco
- University of Washington
第11章 結論
第12章 附錄
圖表一覽
Abstract
Summary
GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D”. The report provides an in-depth analysis on global stem cell research and development. The report suggests investment decisions in stem cell research by providing trends and information on pipelines, federal spending, venture capitalist perspective, country regulations, competitive landscape and market potential. It also provides an analysis on the current investments in various stem cell research segments. In addition to this, the report covers market drivers and challenges for stem cell research and development market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
GBI Research analysis finds that stem cell therapies have immense market potential driven by strong pipeline that caters to high unmet needs. Increasing investment and supportive regulatory environment in key geographies will help the stem cells industry to realize its full potential. Stem cell therapies high market potential is based on their unique ability to offer curative treatment in comparison to the symptomatic treatment offered by conventional treatments. From a commercial perspective, many diseases that arise as a result of irreversible damage to specialized cell types currently have large unmet needs that cannot be served based on conventional pharmaceutical and biotech research. Not serving these unmet needs results in loss of growth opportunities for the pharmaceutical industry. Stem cell research is a technology that has the potential to serve these unmet needs by providing alternatives to conventional pharmaceutical and biotech research which are targeted more at the symptoms than at the cause.
Strategic partnerships between pharmaceutical companies and stem cell research companies are boosting stem cell research and development. Almost 90% of the drugs in clinical trials fail due to factors such as lack of effectiveness and adverse side effects of the drug. Usually animal or tumor cells are being used and this leads to jury-rigged tests. Hence all major pharmaceutical companies are looking forward for new technologies that increase the possibility to launch new therapies in the market place. At present, there has been a spur in investments from pharmaceutical companies into stem cell research through strategic partnerships with stem cell research companies. Major pharmaceutical companies have planned and aligned their objectives to enter the stem cell market in the next 3-5 years, with a few strategic partnerships already formed between pharmaceutical companies and stem cell research based companies. Pharmaceutical companies are also exploring various methods where stem cells could be utilized in drug discovery process to accelerate the discovery of novel drug molecules.
Scope
- Country analysis of regulatory framework, investments, research clusters and overall support including the US, the UK, Germany, France, Japan, China, India, Singapore, Canada, and Australia.
- Investment Analysis in leading geographies.
- In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers.
- Market characterization data for stem cell research including population size, market potential, NIH funding, technology adoption framework and business models.
- Key drivers and restraints that have a significant impact on the market.
- Competitive landscape of global stem cell research including benchmarking of the leading companies. The key companies discussed in this report are Aastrom Biosciences, Athersys, Bioheart, Aldagen, Mesoblast, Geron Corporation, Advanced Cell Technology, Cytori Therapeutics, Pluristem Therapeutics, Medistem, NeoStem, Helix Therapeutics and StemCells Inc.
- Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2011 till date.
Reasons to buy
- Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
- Develop key strategic initiatives by studying the key strategies of top competitors
- Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety
Executive Summary
GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D”. The report provides an in-depth analysis on global stem cell research and development. The report suggests investment decisions in stem cell research by providing trends and information on pipelines, federal spending, venture capitalist perspective, country regulations, competitive landscape and market potential. It also provides an analysis on the current investments in various stem cell research segments. In addition to this, the report covers market drivers and challenges for stem cell research and development market.
The stem cell therapies market has tremendous market potential in future. GBI Research analysis suggests that high unmet need in some of the major chronic diseases and a strong stem cell pipeline in those indications will drive the market growth for stem cell therapies in future. The immense market potential will also result in boost to further research in the area. In addition, increasingly supprove regulatory environment and more investments into stem cell R&D will boost the market prospects in future.
The key reason for the high potential in the stem cell research market is due the ability of stem cell therapies to treat the cause of the disease instead of just managing the symptoms, which is what the current conventional therapies are doing. Looking from a commercial perspective, this deficit of curative treatments leads to loss of growth opportunities for the pharmaceutical industries. This is where, stem cell research provides alternative to the conventional pharmaceutical and biotech research where they provide curative treatment instead of symptomatic, thereby serving the unment need.
Increasing Entry of the Pharmaceutical Companies would Drive the Stem Cell Research and Development
Over the years, there has been a spur in investments from pharmaceutical companies in stem cell research wherein they have collaborated with the stem cell research companies to provide research support. Major pharmaceutical companies have planned and aligned their objectives in the stem cells space for the next five years. Pharmaceutical companies are exploring various methods where stem cells could be utilized in drug discovery process to accelerate the discovery of novel drug molecules. Many top pharmaceutical companies have already begun work along with leading academic and stem cell research companies. These companies ensure that the research projects meet ethical standards. At present, top pharmaceutical companies are investing in stem cell research and some mid-size pharmaceutical companies have shown interest to invest in the future.
GlaxoSmithKline, Pfizer, Novartis, Novo Nordisk, Teva Pharmaceuticals and Roche are few of the top companies that are actively involved in stem cell research. The Hybrid model of stem cell research and development is in the growth stage. In most partnerships, the pharmaceutical companies fund the research and benefit from the outcome of the research work. Stem cell research based companies receive an upfront fee, licensing fee and potential milestone payments. At present, this is the revenue generating model for most stem cell research based companies.
High Unmet Needs and Promising Phase III Trials Boosts Stem Cell Research and Development
The current lack of curative treatments for chronic diseases is expected to be met by Stem cell therapies. In spite of advancements in medical technologies, there are very few treatment options available in the market to cure certain cardiovascular disorders, cancers, autoimmune and inflammatory disorders, spinal cord injury and others. Also, most of these therapies treat the symptoms without curing the disease. Stem cell therapies will help to fill this gap with the use of novel therapeutic approaches that have the ability to cure the disease. Promising pipeline drugs in Phase III has increased the hopes of commercialization of stem cell therapies.
The total number of stem cell clinical trials has increased tremendously over the last few years. With more than 60 ongoing Phase III trials, the market is keenly awaiting the launch of these therapies within the next four to six years. The launch of the drugs in the stem cell research is going to drive the market as a majority of the therapies belong to oncology followed by cardiovascular and immunology related disorders. The Preclinical research and Phase I trials have also increased at a phenomenal rate. This increase demonstrates the emerging interests in stem cell research across the globe.
Favorable Government Regulations and Increase in Investments have Triggered the Growth of Stem Cell Research
In the US, in March 2009, President Barrack Obama undid the ban on the federal funding on stem cell research, including embryonic stem cell research. This opened the doors of Department of Health and Human Services, including National Institutes of Health (NIH), to provide support for human embryonic stem cell research. The largest benefit was to the areas of diabetes, heart diseases and Alzheimer's wherein the funding will enable new therapies and discoveries with better understanding and treatment of these disease conditions to enter the market. Since then, the federal funding and venture capitalists' funding for stem cell research has been increasing steadily and considerably. The trend is expected to continue in future with the amendment from the US government.
Hence, a favorable political and regulatory environment on embryonic stem cell research is expected to drive stem cell research and development to prosper in the US, the largest pharmaceutical market in the world. Between 2001 and 2009, the authority to fund and conduct human embryonic stem cell research was limited by presidential (George W. Bush) directive on restrictions.
Oncology, Cardiovascular and CNS (Central Nervous System) are the Top Three Therapeutics Areas to Receive Considerable Funding from NIH
In 2010, stem cell research in the disease areas of oncology, cardiovascular and CNS disorders accounted for half of the total funding received from NIH. While oncology accounted for the highest funding of 21% of the total funding, cardiovascular and CNS followed with 18% and 11% share in the total funding received from NIH. This suggests that these three areas are the top three areas of research in stem cells. Other major areas that received significant NIH funding included genetic disorders and hematological disorders. Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
2. Stem Cell Research Market to 2017 - Introduction
- 2.1. GBI Research Report Guidance
3. Stem Cell Research Market to 2017- Market Overview
- 3.1. Stem Cell Research - An Introduction
- 3.2. Types of Stem Cell Research
- 3.3. Current Utilization of Different Types of Stem Cells
- 3.4. Unmet Needs
- 3.4.1. Applications of Stem Cell Research
4. Stem Cell Research Market to 2017- Market Characterization
- 4.1. Stem Cell Market - An Introduction
- 4.2. Market Sizing
- 4.3. Therapy Cost
- 4.4. Technology Adoption Framework
- 4.5. Types of Business Models
- 4.6. Market Drivers
- 4.6.1. Immense Market Opportunity for Stem Cell Research for Certain Disorders with High Unmet Need in Terms of Safe and Efficacious Drugs
- 4.6.2. Encouraging Political Environment on Embryonic Stem Cell Research in the US
- 4.6.3. Advances in Induced Pluripotent Stem Cells (iPSC) can Decrease Dependency on Embryonic Stem Cells and Increase the Acceptance of Stem Cell Therapy
- 4.7. Market Barriers & Challenges
- 4.7.1. High Cost of Research Demands High Investments in the Stem Cell Research and Development
- 4.7.2. Uncertain Reimbursement Scenario for Stem Cell Therapies Due to High Treatment Cost and Unclear Cost-Benefit Ratio
- 4.7.3. Ethical, Legal and Social Issues Continue to Remain a Challenge - Albeit with Reduced Impact
- 4.7.4. Management of Best Scientific Talent for Stem Cell Research Based Companies Remains a Key Area of Focus to Sustain High Quality Research
- 4.8. Stem Cell Research and Development - Market Trends
- 4.8.1. Booming Stem Cell Tourism is a Potential Opportunity for Countries to Attract Investments
- 4.8.2. ASLAP Analysis of Stem Cell Tourism
- 4.8.3. Federal Funding Support Improves the Stem Cell Research Environment
- 4.8.4. Increasing Entry of Pharmaceutical Companies Boosts Stem Cell Research & Development
- 4.8.5. PESTLE Analysis of Stem Cell Research
- 4.8.6. SWOT Analysis of Stem Cell Research & Development
- 4.9. Market Analysis
5. Stem Cell Research Market to 2017 - Pipeline Analysis
- 5.1. Discovery
- 5.2. IND Filed
- 5.3. Pre-Clinical
- 5.4. Phase I
- 5.5. Phase II
- 5.6. Phase III
6. Stem Cell Research Market to 2017 - Investment Trends
- 6.1. Investor's Perspective on Stem Cell Research
- 6.1.1. Status of Research
- 6.1.2. Regulatory Position
- 6.1.3. Clinical Development
- 6.1.4. Commercial Models
- 6.1.5. Patent Policy
- 6.2. NIH Spending in Stem Cell Research and Development is Increasing and is Supportive
- 6.2.1. NIH Spending by Therapeutic Areas
- 6.2.2. High Budget Projects Funded by NIH
- 6.3. BBSRC Funding in Stem Cell Research
7. Stem Cell Research Market to 2017 - Geographical Trends
- 7.1. Stem Cell Companies by Geographic Regions
- 7.2. The US
- 7.3. The UK
- 7.4. China
- 7.5. Netherlands
- 7.6. Singapore
- 7.7. South Korea
- 7.8. Japan
- 7.9. India
- 7.10. Sweden
- 7.11. Denmark
- 7.12. France
- 7.13. Germany
- 7.14. Israel
- 7.15. Australia
- 7.16. Canada
- 7.17. Czech Republic
8. Stem Cell Research Market to 2017 - Mergers and Acquisitions
- 8.1. Mergers and Acquisitions
- 8.1.1. Overview
- 8.1.2. Segmentation by Type
- 8.1.3. Segmentation by Region
- 8.2. Licensing Agreements and Co-Development
- 8.2.1. Segmentation by Region
- 8.2.2. Segmentation by Deal Type
9. Stem Cell Research Market to 2017 - Company Profiles
- 9.1. Aastrom Biosciences
- 9.2. Athersys Inc.
- 9.3. Osiris Therapeutics
- 9.4. Bioheart
- 9.5. Aldagen
- 9.6. Mesoblast
- 9.7. Geron
- 9.8. Advanced Cell Technology
- 9.9. Cytori Therapeutics
- 9.10. Pluristem Therapeutics
- 9.11. Medistem
- 9.12. NeoStem
- 9.13. Helix Therapeutics
- 9.14. StemCells Inc.
10. Stem Cell Research Market to 2017- University Profiles
- 10.1. University of California, San Francisco
- 10.2. University of Washington
11. Stem Cell Research Market to 2017 - Conclusion
12. Stem Cell Research Market to 2017- Appendix
- 12.1. Market Definitions
- 12.2. Abbreviations
- 12.3. Methodology
- 12.3.1. Coverage
- 12.3.2. Secondary Research
- 12.3.3. Primary Research
- 12.3.4. Expert Panels
- 12.4. Contact Us
- 12.5. Disclaimer
- 12.6. Sources
List of Tables
- Table 1: Stem Cell Research Market to 2017, Global Sales of Stem Cells, $bn, 2008-2014
- Table 2: Stem Cell Research Market to 2017, Disease Conditions and Prevalence in the US, 2010
- Table 3: Stem Cell Research Market to 2017, Preferred Countries for Stem Cell Tourism, 2011
- Table 4: Stem Cell Research Market to 2017, Pharmaceutical Companies Partnership Environment, 2010-2011
- Table 5: Stem Cell Research Market to 2017, Pipeline Analysis, Discovery, 2011
- Table 6: Stem Cell Research Market to 2017, Pipeline Analysis, IND Filed, 2011
- Table 7: Stem Cell Research Market to 2017, Pipeline Analysis, Preclinical, 2011
- Table 8: Stem Cell Research Market to 2017, Pipeline Analysis, Phase I, 2011
- Table 9: Stem Cell Research Market to 2017, Pipeline Analysis, Phase II, 2011
- Table 10: Stem Cell Research Market to 2017, Pipeline Analysis, Phase III, 2011
- Table 11: Stem Cell Research Market to 2017, the US, NIH Funding, $m, 2002-2010
- Table 12: Stem Cell Research Market to 2017, NIH Funding, Cardiovascular, ($m), 2009-2010
- Table 13: Stem Cell Research Market to 2017, NIH Funding, Central Nervous System, ($m), 2009-2010
- Table 14: Stem Cell Research Market to 2017, NIH Funding, Genetic Disorders, ($m), 2009-2010
- Table 15: Stem Cell Research Market to 2017, NIH Funding, Hematological Disorders, ($m), 2009-2010
- Table 16: Stem Cell Research Market to 2017, NIH Funding, Oncology, ($m), 2009-2010
- Table 17: Stem Cell Research Market to 2017, NIH Funding, Basic Research, ($m), 2009-2010
- Table 18: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009 - May 2011
- Table 19: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009
- Table 20: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2010
- Table 21: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2009
- Table 22: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2010
- Table 23: Stem Cell Research Market to 2017, Segmentation by Funding Mechanism in Therapeutic Areas, 2010
- Table 24: Stem Cell Research Market to 2017, Acquisitions, 2011
- Table 25: Stem Cell Research Market to 2017, Aastrom BioSciences Inc., 2011
- Table 26: Stem Cell Research Market to 2017, Athersys Inc., 2011
- Table 27: Stem Cell Research Market to 2017, Osiris Therapeutics, 2011
- Table 28: Stem Cell Research Market to 2017, Bioheart, 2011
- Table 29: Stem Cell Research Market to 2017, Aldagen, 2011
- Table 30: Stem Cell Research Market to 2017, Mesoblast, 2011
- Table 31: Stem Cell Research Market to 2017, Geron, 2011
- Table 32: Stem Cell Research Market to 2017, Advanced Cell Technology, 2011
- Table 33: Stem Cell Research Market to 2017, Cytori Therapeutics, 2011
- Table 34: Stem Cell Research Market to 2017, Pluristem Therapeutics, 2011
- Table 35: Stem Cell Research Market to 2017, Medistem, 2011
- Table 36: Stem Cell Research Market to 2017, NeoStem, 2011
- Table 37: Stem Cell Research Market to 2017, Helix Therapeutics, 2011
- Table 38: Stem Cell Research Market to 2017, StemCells Inc., 2011
- Table 39: Stem Cell Research Market to 2017, University of California, San Francisco, 2011
- Table 40: Stem Cell Research Market to 2017, University of Washington, 2011
List of Figures
- Figure 1: Stem Cell Research Market to 2017, Stem Cell Research and Development, 2010
- Figure 2: Stem Cell Research Market to 2017, Current Utilization of Different Types of Stem Cells, 2010
- Figure 3: Stem Cell Research Market to 2017, Stem Cells - Interaction Framework, 2011
- Figure 4: Stem Cells Research Market to 2017, Cells Models -Present and the Future, 2011
- Figure 5: Stem Cell Research Market to 2017, Unmet Need vs Time to Market, 2010-2017
- Figure 6: Stem Cell Research Market to 2017, Applications of Stem Cell Research, 2011
- Figure 7: Stem Cell Research Market to 2017, Global Sales of Stem Cells, $bn, 2008-2014
- Figure 8: Stem Cell Research Market to 2017, Technology Adoption Framework, 2011
- Figure 9: Stem Cell Research Market to 2017, Business Models in Stem Cell Industry, 2011
- Figure 10: Stem Cell Research Market to 2017, Treatment Availability - Impact Analysis, 2011
- Figure 11: Stem Cell Research Market to 2017, Political Environnent - Impact Analysis, 2011
- Figure 12: Stem Cell Research Market to 2017, Advances in iPSC - Impact Analysis, 2011
- Figure 13: Stem Cell Research Market to 2017, High Cost of Research - Impact Analysis, 2011
- Figure 14: Stem Cell Research Market to 2017, Reimbursements - Impact Analysis, 2011
- Figure 15: Stem Cell Research Market to 2017, Ethical, Legal and Social Issues - Impact Analysis, 2011
- Figure 16: Stem Cell Research Market to 2017, Human Resources - Impact Analysis, 2011
- Figure 17: Stem Cell Research Market to 2017, ASLAP Analysis of Stem Cell Tourism, 2011
- Figure 18: Stem Cell Research Market to 2017, Federal Funding Trend, 2010
- Figure 19: Stem Cell Research Market to 2017, PESTLE Analysis of Stem Cell Research, 2011
- Figure 20: Stem Cell Research Market to 2017, SWOT Analysis of Stem Cell Research and Development, 2011
- Figure 21: Stem Cell Research Market to 2017, SWOT Analysis of Stem Cell Research and Development - Impact Grid in 2010
- Figure 22: Stem Cell Research Market to 2017, Porter's Five Force Analysis, 2011
- Figure 23: Stem Cell Research Market to 2017, Venture Capitalist's Perspective on Stem Cell Research, 2011
- Figure 24: Stem Cell Research Market to 2017, VC's Perspective on Stem Cell Research - Impact Analysis, 2011
- Figure 25: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009 - May 2011
- Figure 26: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009
- Figure 27: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2010
- Figure 28: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2009
- Figure 29: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2010
- Figure 30: Stem Cell Research Market to 2017, Segmentation of Total Value of Funding by Therapeutic Areas, 2009
- Figure 31: Stem Cell Research Market to 2017, Segmentation of Total Value of Funding by Therapeutic Areas, 2010
- Figure 32: Stem Cell Research Market to 2017, Segmentation of Total Value by the Funding Mechanisms, 2009
- Figure 33: Stem Cell Research Market to 2017, Segmentation of Total Value by Funding Mechanisms, 2010
- Figure 34: Stem Cell Research Market to 2017, Segmentation by Funding Mechanism in Therapeutic Areas, 2010
- Figure 35: Stem Cell Research Market to 2017, Stem Cell Companies by Geographic Regions, 2010
- Figure 36: Stem Cell Research Market to 2017, Country Analysis - The US
- Figure 37: Stem Cell Research Market to 2017, Country Analysis - The UK, 2011
- Figure 38: Stem Cell Research Market to 2017, Country Analysis- China, 2011
- Figure 39: Stem Cell Research Market to 2017, Country Analysis - Netherlands, 2011
- Figure 40: Stem Cell Research Market to 2017, Country Analysis - Singapore, 2011
- Figure 41: Stem Cells Research Market to 2017, Country Analysis - South Korea, 2011
- Figure 42: Stem Cell Research Market to 2017, Country Analysis - Japan, 2011
- Figure 43: Stem Cell Research Market to 2017, Country Analysis - India, 2011
- Figure 44: Stem Cell Research Market to 2017, Country Analysis - Sweden, 2011
- Figure 45: Stem Cell Research Market to 2017, Country Analysis - Denmark, 2011
- Figure 46: Stem Cell Research Market to 2017, Country Analysis - France, 2011
- Figure 47: Stem Cell Research Market to 2017, Country Analysis - Germany, 2011
- Figure 48: Stem Cells Research Market to 2017, Country Analysis - Israel, 2011
- Figure 49: Stem Cell Research Market to 2017, Country Analysis - Australia, 2011
- Figure 50: Stem Cell Research Market to 2017, Country Analysis - Canada, 2011
- Figure 51: Stem Cells Research Market to 2017, Country Analysis - Czech Republic, 2011
- Figure 52: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Deal Type, 2004- May 2011
- Figure 53: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Deal Type, 2004- May 2011
- Figure 54: Stem Cell Research Market to 2017, Segmentation of Licensing Deals Value by Region, 2004 - May 2011
- Figure 55: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Region, 2004 - May 2011
- Figure 56: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Region, 2004 - May 2011
- Figure 57: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Region, 2004 - May 2011
- Figure 58: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Deal Type, 2004 - May 2011
- Figure 59: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Deal Type, 2004 - May 2011
|
 |
